Asset Details
Do you wish to reserve the book?
Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis
Do you wish to request the book?
Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis
2017
Overview
The objective of this study was to evaluate the impact of oral glucocorticoid (GC) dose on rates of hospitalized infectious events (HIEs) among RA patients newly exposed to tumor necrosis factor inhibitor (TNFi) therapy. This retrospective cohort study used data from the MarketScan claims database. Incident and prevalent adult RA patients newly exposed to TNFi therapy were identified and assigned to three cohorts: no GC, low-dose GC (≤7.5 mg), and high-dose GC (>7.5 mg); patients could contribute exposure time to multiple cohorts if they changed dose or discontinued GC. The primary outcome was estimated incidence rate (IR) of HIEs per 100 patient-years of GC exposure. A total of 40,933 eligible patients were identified (mean age 53.0 years; 77.4% female). HIE risk increased with increasing GC dose: the IR [95% confidence interval (CI)] was 3.9 (3.63–4.13) for no GC; 6.4 (5.68–7.16) for low-dose GC; and 13.3 (11.9–15.5) for high-dose GC. Adjusted rate ratios (95% CI) were 1.4 (1.21–1.60) for low-dose vs no GC; 2.8 (2.32–3.34) for high-dose vs no GC, and 2.0 (1.66–2.45) for high-dose vs low-dose GC. The risk of HIEs increased with increasing age. HIE risk did not increase with longer exposure to GCs. Oral GCs, regardless of dose, significantly increased the risk of HIEs among RA patients newly initiating TNFi therapy. Steroid dosing must be considered when assessing infection risk in treatment decisions for RA patients.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Arthritis, Rheumatoid - diagnosis
/ Arthritis, Rheumatoid - drug therapy
/ Arthritis, Rheumatoid - epidemiology
/ Arthritis, Rheumatoid - immunology
/ Biological Products - administration & dosage
/ Biological Products - adverse effects
/ Dose-Response Relationship, Drug
/ Female
/ Glucocorticoids - administration & dosage
/ Glucocorticoids - adverse effects
/ Humans
/ Male
/ Medicine
/ Necrosis
/ Opportunistic Infections - chemically induced
/ Opportunistic Infections - diagnosis
/ Opportunistic Infections - epidemiology
/ Opportunistic Infections - immunology
/ Safety
/ Tumor Necrosis Factor-alpha - antagonists & inhibitors
